4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/302% above fair value
$12.12−0.88 (-6.74%)
Close on Nov 12, 2026Market cap $874.46MP/E –Yield –
4D Molecular Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
4D Molecular Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$212.17M. For fiscal 2025 it was -$154.85M. The highest annual figure on record is -$49.76M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$154.85M | – |
| FY2024 | Dec 31, 2024 | -$183.19M | – |
| FY2023 | Dec 31, 2023 | -$108.66M | – |
| FY2022 | Dec 31, 2022 | -$107.63M | – |
| FY2021 | Dec 31, 2021 | -$69.81M | – |
| FY2020 | Dec 31, 2020 | -$55.22M | – |
| FY2019 | Dec 31, 2019 | -$49.76M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$80.00M | – |
| Q2 FY2026 | Jun 30, 2026 | -$75.75M | – |
| Q1 FY2026 | Mar 31, 2026 | -$72.35M | – |
| Q4 FY2025 | Dec 31, 2025 | $15.93M | – |
| Q3 FY2025 | Sep 30, 2025 | -$59.92M | – |
| Q2 FY2025 | Jun 30, 2025 | -$58.29M | – |
| Q1 FY2025 | Mar 31, 2025 | -$52.57M | – |
| Q4 FY2024 | Dec 31, 2024 | -$55.02M | – |
| Q3 FY2024 | Sep 30, 2024 | -$49.94M | – |
| Q2 FY2024 | Jun 30, 2024 | -$41.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -$36.96M | – |
| Q4 FY2023 | Dec 31, 2023 | -$35.55M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.98M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.08M | – |
| Q4 FY2022 | Dec 31, 2022 | -$27.71M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.98M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.96M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.99M | – |
| Q4 FY2021 | Dec 31, 2021 | -$24.37M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.28M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.23M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.93M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.05M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.45M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.79M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.93M | – |
See a number that looks wrong?